Immunomodulatory effects of telitacicept plus mycophenolate mofetil on B‑cell subsets in patients with systemic lupus erythematosus

Technical Summary: Immunomodulatory Effects of Telitacicept Plus Mycophenolate Mofetil on B‑cell Subsets in SLE

Problem Statement
Systemic lupus erythematosus (SLE) is driven by the abnormal proliferation, differentiation, and subset imbalance of B cells, which contribute to pathogenesis through autoantibody production, antigen presentation, and pro-inflammatory cytokine secretion. Specifically, the expansion of age-associated B cells (ABCs; CD11c+ T-bet+) and plasmablasts correlates with disease activity and organ damage, while regulatory B cells (Bregs) are defective. While telitacicept, a dual BLyS/APRIL inhibitor, has shown clinical efficacy, its dynamic effects on specific B-cell subsets—particularly ABCs and Bregs—and its direct mechanisms of action remain incompletely understood. Furthermore, the potential for combining telitacicept with a reduced dose of mycophenolate mofetil (MMF) to achieve comparable efficacy with reduced toxicity has not been fully explored.

Methodology
The authors conducted a prospective, randomized, open-label controlled trial involving 40 patients with active SLE (SLEDAI-2K ≥ 8) from Shanxi Provincial People's Hospital (January 2022–June 2023). Patients were randomized 1:1 to receive either:

1. Combination Group: Telitacicept (160 mg subcutaneously weekly for 1 month, then monthly) plus reduced-dose MMF (0.5 g twice daily).
2. Control Group: Full-dose MMF (1 g twice daily).
   Both groups received background therapy (hydroxychloroquine/glucocorticoids) for 24 weeks. Twenty healthy individuals served as controls.

Key Measurements:

• Clinical: SLEDAI-2K scores, adverse events.
• Flow Cytometry: B-cell apoptosis rates, absolute B-cell counts, and subset proportions (naive, memory, ABCs, plasmablasts, Bregs) at baseline, weeks 4, 8, 12, and 24.
• Cytokines: Plasma levels of BLyS, IL-10, IL-6, and IL-21 measured via Luminex.
• In Vitro Validation: CD19+ B cells from SLE patients were isolated and stimulated with CpG + IL-21 to induce ABC differentiation. Cells were treated with telitacicept (10 and 100 μg/mL) or mycophenolic acid (MPA) to assess direct inhibition of ABC differentiation and secretion of IgG/IL-6.

Key Results

1. Clinical Efficacy: Both groups showed significant reductions in SLEDAI-2K scores over 24 weeks. The combination group achieved low disease activity (SLEDAI-2K < 6) from week 12 onward. There was no statistically significant difference in disease activity reduction between the two groups.
2. B-Cell Subset Modulation:
   • Pathogenic Subsets: The combination group demonstrated significantly greater reductions in absolute B-cell counts, naive B cells, memory B cells, ABCs, and plasmablasts compared to the MMF-only group at all post-baseline time points.
   • Regulatory Subsets: Both groups saw an increase in Breg proportions, reaching near-healthy levels by week 24, with no significant between-group difference.
   • Apoptosis: The B-cell apoptosis rate decreased significantly in the combination group, reaching a nadir at week 12.
3. Cytokine Profiles:
   • BLyS: Levels decreased significantly in the combination group from week 4 onward, correlating with the decline in B-cell counts. MMF alone did not significantly alter BLyS.
   • Pro-inflammatory Cytokines: IL-6 and IL-21 levels decreased significantly in the combination group after week 8, correlating with the reduction in ABCs.
   • Anti-inflammatory Cytokines: IL-10 levels increased progressively in the combination group, correlating with the rise in Bregs.
4. In Vitro Findings: Telitacicept inhibited ABC differentiation in a concentration-dependent manner and reduced IgG and IL-6 secretion. In contrast, MPA (the active metabolite of MMF) did not exert direct inhibitory effects on ABC differentiation in this model.
5. Safety: The overall incidence of adverse events was lower in the combination group (40.00%) compared to the MMF monotherapy group (70.00%), though the difference did not reach statistical significance (P = 0.057). Notably, serious infections occurred in 10% of the MMF group but 0% of the combination group.

Key Contributions

• Mechanistic Insight: The study provides evidence that telitacicept directly inhibits the differentiation of SLE B cells into ABCs, a pathogenic subset linked to TLR7 gain-of-function variants, rather than acting solely through indirect T-cell suppression.
• Dual-Target Advantage: The data supports the hypothesis that dual BLyS/APRIL blockade (telitacicept) is more effective than single-target or standard immunosuppression (MMF) at reducing plasmablasts and ABCs, likely due to the critical role of APRIL in plasma cell survival.
• Therapeutic Strategy: The findings suggest that combining telitacicept with a reduced dose of MMF can maintain disease control while potentially lowering the risk of adverse events associated with full-dose MMF.
• Homeostasis Restoration: The study highlights a shift from simple B-cell depletion to the restoration of immune homeostasis, characterized by the simultaneous reduction of pathogenic subsets and the recovery of Bregs.

Significance and Claims
The authors claim that this study elucidates the immunomodulatory mechanisms of telitacicept, specifically its ability to reshape B-cell homeostasis by targeting ABCs and plasmablasts while promoting Breg recovery. They posit that the combination of telitacicept and reduced-dose MMF represents a safe and effective therapeutic strategy for active SLE. The in vitro data serves as proof-of-concept that telitacicept directly regulates ABC differentiation, offering a mechanistic explanation for its superior efficacy in reducing specific pathogenic B-cell subsets compared to MMF alone. The authors conclude that while the combination therapy is non-inferior to full-dose MMF in controlling disease activity, it offers a more refined immunomodulatory profile and a favorable safety trend.